The Alzheimer's screening debate in the United States has been dealt a significant blow with the stalling of a crucial federal panel tasked with evaluating preventive health services. The US Preventive Services Task Force (USPSTF) had intended to issue recommendations on cognitive decline screening this year, but its operations have been halted since March 2025 due to a combination of factors, including the firing of two panel chairs by a political appointee and ongoing vacancies.
The disruption raises concerns about the development of evidence-based approaches to early detection of cognitive decline. Dr Robert F Kennedy Jr, US Health Secretary, has publicly championed enhanced screening, even criticising the panel's perceived 'negligence' in April 2025. Despite this criticism, little progress has been made in convening a quorate meeting to address the issue.
Professor John Ruiz, a clinical psychology expert and former USPSTF member, notes that there is currently a lack of consensus among medical professionals on assessment methods for cognitive screening. "You get 10 neurologists, you get 10 approaches on how they're going to assess that – there's no consensus," he explains. "The evidence is mixed at best." This highlights the need for increased funding and dedicated research studies to build stronger evidence.
The USPSTF recommendations are crucial not only for guiding US health policy but also for informing future research directions globally. The draft recommendations typically undergo public comment, often receiving significant input from the scientific community. Alzheimer's researchers have reported that their work has been impacted by related health department policies, including disruptions to funding.
According to NHS sources, an estimated 7.4 million Americans aged 65 and older are affected by Alzheimer's disease, the most common form of dementia. Approximately 200,000 middle-aged individuals also receive a diagnosis each year. Early detection is critical for management and support, but current screening typically begins when symptoms appear, leading to cognitive testing and specialist referrals.